Nucleic Acids Research Advance Access originally published online on January 21, 2008
Nucleic Acids Research 2008 36(5):1555-1566; doi:10.1093/nar/gkm1173
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nucleic Acids Research, 2008, Vol. 36, No. 5 1555-1566
© 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Molecular Biology |
Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage
1Department of Biochemistry and Molecular Biology, Sealy Center for Molecular Medicine, University of Texas Medical Branch, TX-77555, Galveston, USA, 2Department of Biochemistry, Alexandria University, Alexandria, Egypt, 21511 and 3Department of Otolaryngology, Louisiana State University Health Science Center, LA 70112, New Orleans, USA
*To whom correspondence should be addressed. Tel: 409 772 1779; Fax: 409 747 8608; Email: kkbhakat{at}utmb.edu
Received October 31, 2007. Revised December 19, 2007. Accepted December 20, 2007.
The human AP-endonuclease (APE1/Ref-1), an essential multifunctional protein, plays a central role in the repair of oxidative base damage via the DNA base excision repair (BER) pathway. The mammalian AP-endonuclease (APE1) overexpression is often observed in tumor cells, and confers resistance to various anticancer drugs; its downregulation sensitizes tumor cells to those agents via induction of apoptosis. Here we show that wild type (WT) but not mutant p53 negatively regulates APE1 expression. Time-dependent decrease was observed in APE1 mRNA and protein levels in the human colorectal cancer line HCT116 p53(+/+), but not in the isogenic p53 null mutant after treatment with camptothecin, a DNA topoisomerase I inhibitor. Furthermore, ectopic expression of WTp53 in the p53 null cells significantly reduced both endogenous APE1 and APE1 promoter-dependent luciferase expression in a dose-dependent fashion. Chromatin immunoprecipitation assays revealed that endogenous p53 is bound to the APE1 promoter region that includes a Sp1 site. We show here that WTp53 interferes with Sp1 binding to the APE1 promoter, which provides a mechanism for the downregulation of APE1. Taken together, our results demonstrate that WTp53 is a negative regulator of APE1 expression, so that repression of APE1 by p53 could provide an additional pathway for p53-dependent induction of apoptosis in response to DNA damage.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-Y. Heo, K. Jing, K.-S. Song, K.-S. Seo, J.-H. Park, J.-S. Kim, Y.-J. Jung, G.-M. Hur, D.-Y. Jo, G.-R. Kweon, et al. Downregulation of APE1/Ref-1 Is Involved in the Senescence of Mesenchymal Stem Cells Stem Cells, June 1, 2009; 27(6): 1455 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chattopadhyay, S. Das, A. K. Maiti, I. Boldogh, J. Xie, T. K. Hazra, K. Kohno, S. Mitra, and K. K. Bhakat Regulatory Role of Human AP-Endonuclease (APE1/Ref-1) in YB-1-Mediated Activation of the Multidrug Resistance Gene MDR1 Mol. Cell. Biol., December 1, 2008; 28(23): 7066 - 7080. [Abstract] [Full Text] [PDF]
|
|